Long-term sequelae in Ebola Virus disease survivors receiving anti-Ebola virus therapies in the Democratic Republic of the Congo : a prospective cohort study

2025

Article référencé dans le Web of Science WOS:001548889300001

Dilu-Keti A., Tovar-Sanchez T., Cuer Benjamin, Nkuba-Ndaye A., Mukadi-Bamuleka D., Panzi-Kalunda E., Kitenge-Omasumbu R., Bulabula-Penge J., Mambu-Mbika F., Mbala-Kingebeni P., Ayouba Ahidjo, Muyembe-Tamfum J. J., Etard Jean-François, Chenge F., Delaporte E., Ahuka-Mundeke S.

Open Forum Infectious Diseases, 2025, 12 (8), p. ofaf436 [13 p.] ISSN 2328-8957

Background The 2018-2020 Ebola outbreak in the Democratic Republic of the Congo marked the first major cohort of Ebola survivors treated with advanced therapeutics, including monoclonal antibodies (REGN-EB3, ansuvimab, ZMapp) and remdesivir. This study explored factors influencing long-term sequelae in survivors who received these specific therapies.Methods A prospective multicenter study enrolled 750 Ebola survivors from the 10th outbreak in the Democratic Republic of the Congo between April and October 2020. Participants were followed for 12 months to assess the recurrence of clinical sequelae according to Weibull and shared frailty models.Results Of 750 of Ebola survivors, 650 (86.7%) experienced post-Ebola sequalae. The median age of survivors was 32 years and 56.7% were female. Among them, 463 (61.7%) experienced neurologic sequelae, 373 (49.7%) musculoskeletal sequelae, and 288 (38.4%) general sequelae. Globally, these persisted for at least 38 months postdischarge, with slight decreases over time. At enrollment (median time to baseline visit, 330 days after discharge), neurologic sequelae were more frequent in the REGN-EB3 group (hazard ratio, 2.14; 95% CI, 1.28-3.57) as compared with the remdesivir group. Musculoskeletal sequelae were associated with age (1.02; 1.00-1.03), ZMapp treatment (3.17; 1.81-5.56), and acute-phase hemorrhagic symptoms (1.64; 1.14-2.36). Ocular sequelae were associated with age (1.04; 1.02-1.06). Female sex, older age, metabolic comorbidities, and REGN-EB3 therapy were associated with recurrent neurologic and musculoskeletal sequelae. Recurrent ocular sequelae were more frequent in adults (1.02; 1.01-1.03).Conclusions Despite improved survival with monoclonal antibody therapy, our findings highlight a high incidence of neurologic sequelae in the REGN-EB3 group and musculoskeletal sequelae in the ZMapp group as compared with the remdesivir group, as well as among older survivors, women, and those with comorbidities. These results underscore the need for targeting long-term care to effectively manage post-Ebola sequelae.

Santé : généralités [050] ; Entomologie médicale / Parasitologie / Virologie [052]

REPUBLIQUE DEMOCRATIQUE DU CONGO

Fonds IRD [F B010094856]

fdi:010094856